The purpose of this study was to evaluate the effectiveness and utility of 5-fluorouracil (5-FU) and high-concentration cisplatin in advanced hepatocellular carcinoma (HCC) patients receiving short-term (3-day FPL) hepatic arterial infusion chemotherapy.
30 patients with advanced HCC that was unresectable were included in the study. A fine-powder formulation of cisplatin in suspended, pre-warmed lipiodol on Day 2 and hepatic arterial infusion chemotherapy with 5-FU on Days 1-3 were administered to the patients via the implanted port system every 4 to 10 weeks. CT was utilised to evaluate the tumour response one month later. The prognosis is often bad for patients with advanced HCC. The study's findings showed that every patient had signs of portal vein invasion (Vp2-4). Seven patients had stable disease, eight patients had partial responses, and four patients had complete responses (SD). Overall survival (OS) and progression-free survival (PFS) had medians of 198 days and 452 days, respectively. The successful disease control group (CR, PR, and SD) had an OS that was considerably longer than the disease progression group (P .005). Three-day FPL demonstrated efficacy and tolerance in patients with advanced HCC due to its rapid delivery than conventional FP therapy. Thus, recurring 3-day FPL, which looks to be efficient, appears to enhance the prognosis and quality of life of patients with advanced HCC.Author(s) Details:
Yutaka Yata,
Department of Hepatology, Osaka Metropolitan University, Japan and Department of Gastroenterology, Hanwa Memorial Hospital, Japan.
Please see the link here: https://stm.bookpi.org/CIMMS-V1/article/view/8108
No comments:
Post a Comment